» Articles » PMID: 34127625

IRIS METASTASIS FROM BREAST CANCER SUCCESSFULLY TREATED WITH ABEMACICLIB AND LETROZOLE

Overview
Specialty Ophthalmology
Date 2021 Jun 15
PMID 34127625
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To describe a patient with an unusual presentation of iris metastasis from breast cancer and her response to systemic therapy.

Methods: Retrospective chart review of one patient.

Results: A 57-year-old woman presented with a superonasal translucent vascularized iris stromal mass with fish egg-like structures budding from the surface. High-frequency anterior segment ultrasonography demonstrated a solid iris stromal mass measuring 6.0 mm × 3.3 mm × 1.9 mm. On optical coherence tomography, the egglike structures appeared as hyperreflective spheres, some of which were detached from the main iris stromal tumor. Oncologic evaluation revealed metastatic breast cancer involving the brain and lung. She was treated with oral abemaciclib and letrozole, as well as external beam radiotherapy to the brain. The iris mass had completely regressed within 4 months and remained undetectable through the 8-month follow-up. The other metastatic lesions responded well to therapy.

Conclusion: A case of iris metastasis was reported as the presenting sign of cancer dissemination that was successfully treated with targeted systemic therapy without ocular radiotherapy.

Citing Articles

A Case of Metastatic Iris Tumor from Adenocarcinoma of the Cecum Diagnosed by Combined Tumor Markers in Aqueous Humor and Fine Needle Aspiration Cytology.

Mitamura M, Kase S, Suimon Y, Hashimoto Y, Watanabe R, Matsuno Y Case Rep Oncol. 2025; 18(1):29-34.

PMID: 39980514 PMC: 11668533. DOI: 10.1159/000542905.


Successful management of bilateral orbital metastases from invasive lobular breast cancer with abemaciclib and letrozole: a case report and literature review.

Rodrigues Alves N, Duarte A, Ribeiro D, Silva R, Carvalho B, Costa D Front Oncol. 2024; 14:1286910.

PMID: 38322413 PMC: 10845133. DOI: 10.3389/fonc.2024.1286910.